Inflammatory bowel disease and colorectal cancer;Gyulladásos bélbetegségek és colorectalis rák

Orvosi Hetilap

Volumn 147, Issue 41, 2006, Pages 1977-1982

  Hagymási, Krisztina ^a,b   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Gasztroenterológiai és Endokrin Kutatócsoport ^*  (Hungary)

Author keywords

Chemoprevention; Colonoscopy; Colorectal cancer; Inflammatory bowel disease; Pathogenesis; Risk factor; Small bowel cancer; Surveillance

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN A; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID;

CANCER MORTALITY; CANCER RISK; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; ENTERITIS; FAMILY HISTORY; GEOGRAPHIC DISTRIBUTION; HUMAN; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; COLORECTAL TUMOR; HEALTH SURVEY; INCIDENCE; INTESTINE TUMOR; MASS SCREENING; PATHOPHYSIOLOGY; SCLEROSING CHOLANGITIS; SMALL INTESTINE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; CROHN DISEASE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MASS SCREENING; MESALAMINE; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS;

EID: 34249780308     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Askling, J., Dickman, P. W., Karlen, P. és mtsai: Familiy history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology, 2001, 120, 1356-1362.
2. Canavan, C., Abrams, K. R., Mayberry, Et. J.: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther., 2006, 23, 1097-1104.
3. Carrier, J., Medline, A., Sohn, K-J. és mtsai: Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2-and β2-microglobulin-deficient mice. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 1262-1267.
4. Carter, M. J., Lobo, A. J., Travis, S. P. L. és mtsai: Guidelines for the management of inflammatory bowel disease in adults. Gut, 2004, 53 (Suppl. V), v1-v16.
5. Chambers, W. M., Warren, B. F., Jewll, D. P. és mtsa: Cancer surveillance in ulcerative colitis. Br. J. Surg., 2005, 92, 928-936.
6. Croog, V. J., Ullmann, T. A., Itzkowitz, S. H.: Chemoprevention of colorectal cancer in ulcerative colitis. Int. J. Colorectal Dis., 2003, 18, 392-400.
7. Eaden, J.: Review article: colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther., 2004, 20 (Suppl. 4), 24-30.
8. Eaden, J.: Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal patients with inflammatory bowel disease. Aliment. Pharamacol. Ther., 2003, 18 (Suppl. 2): 15-21.
9. Ekbom, A., Helmick, C., Zack, M. és mtsa: Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med., 1990, 323, 1228-1233.
10. Fujii, S., Fujimori, T., Chiba, T. és mtsa: Efficacy of surveillance and molecular markers for detection of ulcerative colitis-associated colorectal neoplasia. J. Gastroenterol., 2003, 38, 1117-1125.
11. Gasche, C.: The chemoprevention of colorectal carcinoma. Aliment. Pharmacol. Ther., 2004, 20 (Suppl. 4.), 31-35.
12. Greenstein, A. J., Sachar, D. B., Smith, D. B. és mtsai: Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology, 1979, 77, 290-294.
13. Hanauer, S. B.: Review article: aminosalicylates in inflammatory bowel disease. Aliment. Pharamcol. Ther., 2004, 20 (Suppl. 4.), 60-65.
14. Inadomi, J. M.: Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand. J. Gastroent., 2003, 237, 17-21.
15. Itzkowitz, S. H., Yio, X.: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol, Gastrointestinal Liver Physiol., 2004, 287, G7-17.
16. Itzkowitz, S.: Colon carcinogenesis in inflammatory bowel disease. J. Clin. Gastroenterol., 2003, 36 (Suppl. 1), S70-74.
17. Itzkowitz, S. H., Harpaz, N.: Diagnosis and management of dysplasia in patients with inflammatory bowel disease. Gastroeneterology, 2004, 126, 1634-1648.
18. Jess, T., Loftus, E. V., Velayos, F. S. és mtsai: Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology, 2006, 130, 1039-1046.
19. Loftus, E. V.: Does monitoring prevent cancer in inflammatory bowel disease? J. Clin. Gastroenterol., 2003, 36 (Suppl. 1.), S79-S83.
20. Matula, S., Croog, V., Itzkowitz, S. és mtsai: Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroent. Hepatol., 2005, 3, 1015-1021.
21. Pardi, D. S., Loftus, E. V., Kremers, W. K. és mtsai: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology, 2003, 124, 889-893.
22. Rubin, D. T.: The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology, 2006, 130, 1350-1362.
23. Rutter, M. D., Saunders, B. P., Wilkinson, K. H. és mtsai: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology, 2006, 130, 1030-1038.
24. Rutter, M. D., Saunders, B. P., Wilkonson, K. H. és mtsai: Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointestinal Endoscopy, 2004, 60, 334-339.
25. Rutter, M., Saunders, B., Wilkinson, K. és mtsai: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 2004, 126, 451-459.
26. Rutter, M. D., Saunders, B. P., Wilkinson, K. H. és mtsai: Cancer surveillance in longstanding ulcerative colitis: endocopic appearence help predict cancer risk. Gut, 2004, 53, 1813-1816.
27. Sandborn, W. J.: Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy, expectations and dose response, complience, and chemoprevention. Rev. Gastroenterol. Dis., 2006, 6, 97-105.
28. Shetty, K., Rybicki, L., Brzezinski, A. és mtsai: The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am. J. Gastroent., 1999, 94, 1643-1649.
29. Stad, T. P., Card, T., Logan, R. F. és mtsa: 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 2005, 54, 1573-1578.
30. Toruner M., Harewood, G. C., Loftus, E. V. és mtsai: Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflammatory Bowel Dis., 2005, 11, 428-434.
31. Ullman, T. A.: Preventing neoplastic progression in ulcerative colitis. J. Clin. Gastroent., 2005, 39 (Suppl. 2.), S66-S69.
32. Ullman, T. A.: Colonoscopic surveillance in inflammatory bowel disease. Curr. Op. Gastroenterol., 2005, 21, 585-588.
33. Van Bodegraven, A. A., Terhaar, J. S.: Mesalazine therapy and ulcerative colitis-A long-term friendship. Business briefing: European Gastroenterology Review, 2005, 37-38. old.
34. Van de Vrie, de Man, W., van Buuren, R. A., Schouten, H. R. és mtsai: Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur. J. Gastroent. Hepatol., 2003, 15, 657-663.
35. Velayos, F. S., Loftus, E. V., Jess, T. és mtsai: Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology, 2006, 130, 1941-1949.